Contagion Editorial Team

home / authors / contagion-editorial-team

Articles

Looking at Asymptomatic Vs. Symptomatic COVID-19 Patients

Looking at Asymptomatic Vs. Symptomatic COVID-19 Patients

Contagion Editorial Team
August 7th 2020

A study suggests that both have similar cycle thresholds but the virus lays dormat in an overwhelming majority of asymptomatic patients.

Read More

Webinar: Race for a COVID-19 Vaccine

Webinar: Race for a COVID-19 Vaccine

Contagion Editorial Team
July 30th 2020

MJH Life Sciences is presenting a webinar today on this important topic.

Read More

Contagion Rapid Readout: A Clinical Review of Remdesivir for COVID-19

Contagion Rapid Readout: A Clinical Review of Remdesivir for COVID-19

Contagion Editorial Team
July 24th 2020

A discussion between providers on 3 studies related to the antiviral.

Read More

HIV Prevention Strategies Beyond PrEP, Catalyzing Clinic Improvement

HIV Prevention Strategies Beyond PrEP, Catalyzing Clinic Improvement

Contagion Editorial Team
October 22nd 2019

Gregory Felzien, MD, AAHIVS, discusses prevention beyond PrEP and creating a safe environment for patients with HIV.

Read More

<12345

Latest Updated Articles

Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Antimicrobial Resistance: Cause for Concern and Optimism?
Published: November 22nd 2024 | Updated: November 27th 2024
Antimicrobial Resistance: Cause for Concern and Optimism?
Respiratory Vaccines Update
Published: November 22nd 2024 | Updated: November 27th 2024
Respiratory Vaccines Update
7-Day Antibiotic Regimen Found Noninferior to 14-Day Treatment for Bloodstream Infections
Published: November 21st 2024 | Updated: November 27th 2024
7-Day Antibiotic Regimen Found Noninferior to 14-Day Treatment for Bloodstream Infections
Two Years After its FDA Approval, Rebyota Continues to Show Efficacy and Safety
Published: November 18th 2024 | Updated: November 27th 2024
Two Years After its FDA Approval, Rebyota Continues to Show Efficacy and Safety
Imdusiran for Chronic Hepatitis B Achieves Functional Cure in 50% of Patients
Published: November 18th 2024 | Updated: November 27th 2024
Imdusiran for Chronic Hepatitis B Achieves Functional Cure in 50% of Patients
© 2024 MJH Life Sciences

All rights reserved.